Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2020, 29(3):173-192

Cytokines in relation to heart failure

Steinkamp R1, Radosinska J1, 2
1 Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Bratislava
2 Center of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic

It is accepted that heart failure (HF) is largely influenced by inflammation. Since cytokines are the main "hormones" of the immune system, they have increasingly received attention in this context, especially due to the observation that blood levels of various cytokines correspond to the clinical outcomes of HF. The purpose of this review is to provide information about the cytokines involved in the HF syndrome, their connection to this disease and implementation in new treatment choices. Another aim is to elaborate on the complex relationship between the cytokines and the neurohumoral axis and involvement of inflammatory escalation in chronic HF. The increased bioavailability of specific inflammatory molecules indicates that inflammation is an omnipresent factor during HF. It is responsible for its induction and progression, but also for its maintenance, including remodeling and regeneration; or even the reoccurrence of adverse cardiac events. Nowadays, cytokines impose a conundrum: a problem that currently cannot be solved. Cytokines needed for the innate immune response are the same, which cause several diseases. Similarly, cytokines supposedly beneficial in the HF setting, can also be the cause of its clinical deterioration. This is the reason why we still do not possess adequate anti-cytokine therapy for HF treatment.

Keywords: cytokines; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; inflammation

Published: March 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Steinkamp R, Radosinska J. Cytokines in relation to heart failure. Cardiology Letters. 2020;29(3):173-192.
Download citation

References

  1. Bartekova M, Radosinska J, Jelemensky M, et al. Role of cytokines and inflammation in heart function during health and disease. Heart failure reviews 2018;23:733-758. Go to original source...
  2. Dinarello CA. Historical review of cytokines1. European journal of immunology 2007;37(Suppl 1):34-45. Go to original source...
  3. Zhang JM, An J. Cytokines, inflammation and pain. International anesthesiology clinics 2007;45:27-37. Go to original source...
  4. Gonçalvesová E. Srdcové zlyhávanie 2017. Na komplexný a individuálny problém treba hľadať komplexné a individualizované riešenie. Cardiology Lett. 2018;27:192-193.
  5. Van Linthout S, Tschöpe C. Inflammation - cause or consequence of heart failure or both? Current Heart Failure Reports 2017;14:251-265. Go to original source...
  6. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. JACC 1992;20:248-254. Go to original source...
  7. Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. Journal of cardiac failure 1996;2:243-249. Go to original source...
  8. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. The New England journal of medicine 2004;350:1953-1959. Go to original source...
  9. Loffredo FS, Nikolova AP, Pancoast JR, et al. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circulation research 2014;115:97-107. Go to original source...
  10. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JACC 2012;59:998-1005. Go to original source...
  11. Riehle C, Bauersachs J. Entzündungsmechanismen bei Herzinsuffizienz. Herz 2019;44:96-106. Go to original source...
  12. Sharma K, Kass DA. Unmet Needs in Cardiovascular Science and Medicine: Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 2014;115:79-96. Go to original source...
  13. Yang D, Elsner SG, Bian ZM, et al. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Experimental eye research 2007;85:462-472. Go to original source...
  14. Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology 2011;127:701721. Go to original source...
  15. Melenovsky V, Petrak J, Mracek T, et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail. 2017;19:522-530. Go to original source...
  16. Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev 2014;19:681-694. Go to original source...
  17. Park M, Sandner P, Krieg T. cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. Basic Research in Cardiology 2018;113:24. Go to original source...
  18. Inserte J, Garcia-Dorado D. The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism. British Journal of Pharmacology 2015;172:1996-2009. Go to original source...
  19. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. JACC 2013;62:263-271. Go to original source...
  20. Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011;4:44-52. Go to original source...
  21. De Angelis E, Pecorano M, Rusciano MR, et al. cross-talk between neurohormonal pathways and the immune system in heart failure: A review of the literature. International journal of molecular sciences 2019;20(7). Go to original source...
  22. Velagaleti RS, Gona P, Pencina MJ, et al. Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. The American journal of cardiology 2013;113(1). Go to original source...
  23. Samak M, Fatullayev J, Sabashnikov A, et al. Cardiac hypertrophy: an introduction to molecular and cellular basis. Medical Science Monitor Basic Research 2016;22:75-79. Go to original source...
  24. Roe ÅT, Sjaastad I, Louch WE. Hjertesvikt med bevart ejeksjonsfraksjon. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke 2017;137(18). Go to original source...
  25. Panera N, Gnani D, Piermarini E, et al. high concentrations of H2O2 trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes. Experimental and Molecular Pathology 2016;100:199-206. Go to original source...
  26. Sciarretta S, Sadoshima J. New insights into the molecular phenotype of eccentric hypertrophy. Journal of molecular and cellular cardiology 2010;49:153-156. Go to original source...
  27. Nakayama H, Bodi I, Maillet M, et al. The IP3 receptor regulates cardiac hypertrophy in response to select stimuli. Circulation research 2010;107:659-666. Go to original source...
  28. Eisner DA, Caldwell JL, Kiasmas K, et al. Calcium and excitation-contraction coupling in the heart. Circulation research 2017;121:181-195. Go to original source...
  29. Li MO, Flavell RA. TGF-β: A master of all T cell trades. Cell 2008;134:392-404. Go to original source...
  30. Ma ZG, Yuan YP, Wu HM, et al. Cardiac fibrosis: new insights into the pathogenesis. International Journal of Biological Sciences 2018;14:1645-1657. Go to original source...
  31. Marsh SA, Arthur HM, Spyridopoulos I. The secret life of nonclassical monocytes. Cytometry. Part A: the journal of the International Society for Analytical Cytology 2017;91:1055-1058. Go to original source...
  32. Chan T, Pek EA, Huth K, et al. CD4+ T-cells are important in regulating macrophage polarization in C57BL/6 wild-type mice. Cellular Immunology 2011;266:180-186. Go to original source...
  33. Zhang F, Wang H, Wang X, et al. TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget 2016;7:5229452306. Go to original source...
  34. Larose E, Rodés-Cabau J, Pibarot P, et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction: traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. JACC 2010;55:2459-2469. Go to original source...
  35. Vieira JM, Norman S, Villa Del Campo C, et al. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. The Journal of Clinical Investigation 2018;128:3402-3412. Go to original source...
  36. Lee KM, Jeon SM, Cho HJ. Interleukin-6 induces microglial CX3CR1 expression in the spinal cord after peripheral nerve injury through the activation of p38 MAPK. European journal of pain (London, England) 2010;1:682 Go to original source...
  37. Pluznik DH, Frappier N, Nordan RP. Interleukin 6 (interferon beta 2) and interferon alpha/beta present in postendotoxin serum induce differentiation of murine M1 myeloid leukemia cells. Experimental hematology 1989;17:1063-1066.
  38. Fu XL, Duan W, Su CY, et al. Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression. Cancer immunology, immunotherapy 2017:1597-1608. Go to original source...
  39. Bansal SS, Ismahil MA, Goel M, et al. Activated T-lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circulation. Heart failure 2017;10(3). Go to original source...
  40. Cihakova D. Interleukin-10 stiffens the heart. The Journal of Experimental Medicine 2018;215:379-381. Go to original source...
  41. Frantz S, Kobzik L, Kim YD, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. Journal of Clinical Investigation 1999;104:271-280. Go to original source...
  42. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nature reviews. Cardiology 2016;14:30-38. Go to original source...
  43. Galindo M, Santiago B, Palao G, et al. Coexpression of AT1 and AT2 receptors by human fibroblasts is associated with resistance to angiotensin II. Peptides 2005;26:1647-1653. Go to original source...
  44. Grotendorst GR, Smale G, Pencev D. Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. Journal of cellular physiology 1989;140:396-402. Go to original source...
  45. Evans RA, Tian YC, Steadman R, Phillips AO. TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Experimental cell research 2003;282:90-100. Go to original source...
  46. Beyer C, Zenzmaier C, Palumbo-Zerr K, et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Annals of the rheumatic diseases 2015;74:1408-1416. Go to original source...
  47. Kovacic JC, Mercader N, Torres M, et al. Epithelial- and Eendothelial- to mesenchymal transition: from cardiovascular development to disease. Circulation 2012;125:1795-1808. Go to original source...
  48. Chen PY, Qin L, Baeyens N, et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest 2015;125:4514-4528. Go to original source...
  49. Gunaratne A, Thai BL, Di Guglielmo GM. Atypical protein kinase c phosphorylates par6 and facilitates transforming growth factor β-induced epithelial-to-mesenchymal transition. Molecular and Cellular Biology 2013;33:874-886. Go to original source...
  50. Pinto MT, Melo F, Ursoli F, et al. Endothelial cells from different anatomical origin have distinct responses during SNAIL/TGFβ2-mediated endothelial-mesenchymal transition. American Journal of Translational Research 2018;10:4065-4081.
  51. Zhous L, Yan C, Gierling RG, et al. Tumor necrosis factor-alpha induced expression of matrix metalloproteinase-9 through p21-activated Kinase-1. BMC Immunology 2009;10:15. Go to original source...
  52. Halade GV, Jin YF, Lindsey ML. Matrix Metalloproteinase (MMP)9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacology & therapeutics 2013;139:32-40. Go to original source...
  53. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011;123(2263-2273. Go to original source...
  54. Hall KC, Bernier SG, Jacobson S, et al. sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH. Proceedings of the National Academy of Sciences of the United States of America 2019;116:11057-11062. Go to original source...
  55. Chaudhury A, Howe PH. The tale of transforming growth factor-β (TGF&beta) signaling: A Soigné Enigma. IUBMB life 2009;61:929939. Go to original source...
  56. Pendergrass KD, Gwathmey TM, Michalek RD, et al. The angiotensin II-AT1 receptor stimulates reactive oxygen species within the cell nucleus. Biochemical and biophysical research communications 2009;384:149-154. Go to original source...
  57. Labandeira-Garcia JL, Rodríguez-Perez AI, Garrido-Gil P, et al. Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration. Frontiers in Aging Neuroscience 2017;9. Go to original source...
  58. Pearl MH, Grotts J, Rossetti M, et al. Cytokine profiles associated with angiotensin ii type 1 receptor antibodies. Kidney international reports 2019;4:541-550. Go to original source...
  59. Wei SG, Yu Y, Zhang ZH, t al. Pro-inflammatory cytokines upregulate sympathoexcitatory mechanisms in the subfornical organ of the rat. Hypertension 2015;65:1126-1133. Go to original source...
  60. Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Research & Therapy 2014;16. Go to original source...
  61. Hara MR, Kovacs JJ, Whalen EJ, et al. A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1. Nature 2011;477(7364):349-353. Go to original source...
  62. Strosberg AD. Structure, function, and regulation of adrenergic receptors. Protein Science: A Publication of the Protein Society 1993;2:1198-1209. Go to original source...
  63. Grisanti LA, Woster AP, Dahlman J, et al. α1-adrenergic receptors positively regulate toll-like receptor cytokine production from human monocytes and macrophages. The Journal of Pharmacology and Experimental Therapeutics 2011;338:648-657. Go to original source...
  64. Scanzano A, Cosentino M. Adrenergic regulation of innate immunity: a review. Frontiers in Pharmacology 2015;6. Go to original source...
  65. De Vito P. Atrial natriuretic peptide: An old hormone or a new cytokine? Peptides 2014;58:108-116. Go to original source...
  66. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012;119:651-665. Go to original source...
  67. Chiurchiu V, Izzi V, D'aquilio F, et al. Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regulatory Peptides 2008;148:26-32. Go to original source...
  68. Ogawata T, de Bold AJ. Brain natriuretic Peptide production and secretion in inflammation. Journal of transplantation 2012:962347. Go to original source...
  69. Nakanishi K. Unique action of Interleukin-18 on T cells and other immune cells. Frontiers in Immunology 2018;9. Go to original source...
  70. Morishita T, Uzui H, Mitsuke Y, et al. Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure. ESC Heart Failure 2017;4:321-330. Go to original source...
  71. Raj L, Adhyaru B. An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF). Postgraduate medical journal 2016;92(1094):726-734. Go to original source...
  72. Pinilla-Vera M, Hahn VS, Kass DA. Leveraging signaling pathways to treat heart failure with reduced ejection fraction. Circulation research 2019;124:1618-1632. Go to original source...
  73. Tschöpe C, Cooper LT, Torre-Amione G, et al. Management of myocarditis-related cardiomyopathy in adults. Circulation research 2019;124:1568-1583. Go to original source...